SCOPE: The potential benefit of vitamin K as a therapeutic in osteoporosis is controversial and the vitamin K regimen being used clinically (45 mg/day) employs doses that are many times higher than required to ensure maximal gamma-carboxylation of the vitamin K-dependent bone proteins. We therefore tested the hypothesis that vitamin K catabolites, 5-carbon (CAN5C) and 7-carbon carboxylic acid (CAN7C) aliphatic side-chain derivatives of the naphthoquinone moiety exert an osteotrophic role consistent with the treatment of osteoporosis. METHODS AND RESULTS: Osteoblast-like MG63 cell cultures were challenged with lipopolysaccharide and the levels of interleukin-6, an osteoclastogenic cytokine, measured with and without catabolites; low concentrations of CAN7C significantly inhibited interleukin-6 release, but CAN5C did not. In models of bone loss induced by ovariectomy or sciatic neurectomy in C57BL/6 mice, we found that the rarer CAN7C catabolite markedly restricted ovariectomy-induced bone loss and possibly limited sciatic neurectomy-induced bone loss. CAN7C activity depends on a free carboxylic acid and its particular side-chain structure. CONCLUSION: These in vivo data indicate for the first time that the clinical utility of vitamin K for osteoporosis may reside in an unusual catabolite.
SCOPE: The potential benefit of vitamin K as a therapeutic in osteoporosis is controversial and the vitamin K regimen being used clinically (45 mg/day) employs doses that are many times higher than required to ensure maximal gamma-carboxylation of the vitamin K-dependent bone proteins. We therefore tested the hypothesis that vitamin K catabolites, 5-carbon (CAN5C) and 7-carbon carboxylic acid (CAN7C) aliphatic side-chain derivatives of the naphthoquinone moiety exert an osteotrophic role consistent with the treatment of osteoporosis. METHODS AND RESULTS: Osteoblast-like MG63 cell cultures were challenged with lipopolysaccharide and the levels of interleukin-6, an osteoclastogenic cytokine, measured with and without catabolites; low concentrations of CAN7C significantly inhibited interleukin-6 release, but CAN5C did not. In models of bone loss induced by ovariectomy or sciatic neurectomy in C57BL/6 mice, we found that the rarer CAN7C catabolite markedly restricted ovariectomy-induced bone loss and possibly limited sciatic neurectomy-induced bone loss. CAN7C activity depends on a free carboxylic acid and its particular side-chain structure. CONCLUSION: These in vivo data indicate for the first time that the clinical utility of vitamin K for osteoporosis may reside in an unusual catabolite.
Authors: Aymen I Idris; Maala Krishnan; Petra Simic; Euphemie Landao-Bassonga; Patrick Mollat; Slobodan Vukicevic; Stuart H Ralston Journal: FASEB J Date: 2010-07-20 Impact factor: 5.191
Authors: Mary L Bouxsein; Stephen K Boyd; Blaine A Christiansen; Robert E Guldberg; Karl J Jepsen; Ralph Müller Journal: J Bone Miner Res Date: 2010-07 Impact factor: 6.741
Authors: Roberto L de Souza; Andrew A Pitsillides; Lance E Lanyon; Timothy M Skerry; Chantal Chenu Journal: J Bone Miner Res Date: 2005-08-08 Impact factor: 6.741
Authors: N Emaus; C G Gjesdal; B Almås; M Christensen; A S Grimsgaard; G K R Berntsen; L Salomonsen; V Fønnebø Journal: Osteoporos Int Date: 2009-11-25 Impact factor: 4.507
Authors: Neil Binkley; Judith Harke; Diane Krueger; Jean Engelke; Nellie Vallarta-Ast; Dessa Gemar; Mary Checovich; Richard Chappell; John Suttie Journal: J Bone Miner Res Date: 2009-06 Impact factor: 6.741
Authors: Sarah L Booth; Gerard Dallal; M Kyla Shea; Caren Gundberg; James W Peterson; Bess Dawson-Hughes Journal: J Clin Endocrinol Metab Date: 2008-02-05 Impact factor: 5.958
Authors: Martin Schubert; Stefan Kluge; Lisa Schmölz; Maria Wallert; Francesco Galli; Marc Birringer; Stefan Lorkowski Journal: Antioxidants (Basel) Date: 2018-01-12